AGAAmerican Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
Abbreviations used in this paper
Cited by (0)
Reprint requests Address requests for reprints to: Chair, Clinical Practice and Quality Management Committee, AGA National Office, 4930 Del Ray Avenue, Bethesda, Maryland 20814[email protected]; telephone: (301) 222-4003.
Conflicts of interest The authors disclose the following: Dr Inadomi has served as a consultant for Takeda, AstraZeneca, and Roche and as associate editor of American Journal of Gastroenterology. Dr Hanauer has served as a consultant for Abbott Laboratories, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Elan, Exagen Diagnostics, Ferring Pharmaceuticals, Genentech, Gilead, Glycominds, GlaxoSmithKline, Hospira, Janssen, Lilly, Meda, Millennium Pharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prometheus, Salix Pharmaceuticals, Sanofi-Aventis, Shire, Takeda, UCB, and Warner Chilcott. The remaining authors disclose no conflicts.